Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Genet Med. 2008 Oct;10(10):720–729. doi: 10.1097/GIM.0b013e3181863239

Table 3.

Association Analysis of DME Genetic Effects with Safety and Efficacy Phenotypes in Each of the Tested Drug Cohorts: (a) Olanzapine; (b) Perphenazine; (c) Quetiapine; (d) Risperidone; (e) Ziprasidone

(a) Olanzapine
CYP1A2
*1F		 p-value
(Pearson/
Fisher’s
exact)		 p-value
(L-R test)		 FMO3 p-value
(Pearson/
Fisher’s
exact)		 p-value
(L-R test)
Genotype LL HL HH MM MN NN
Safety
test 		Disc. Due to ADRs 5 25 28 0.92 0.42 16 22 21 0.24 0.73*
Treatment
completion		 13 52 58 21 58 45
Efficacy
test 		Disc. Due to
inadequate efficacy		 4 6 15 0.22 0.51 4 13 8 0.89 0.78
Treatment
completion		 13 52 58 21 58 45
(b) Perphenazine
CYP2D6 p-value
(Pearson/
Fisher’s exact)		 p-value
(L-R test)
Genotype PM IM EM
Safety test Disc. Due to ADRs 1 5 18 0.13 0.93
Treatment completion 0 5 46
Efficacy
test 		Disc. Due to inadequate
efficacy		 0 0 20 0.31 0.09
Treatment completion 0 5 46
(c) Quetiapine
CYP3A5 p-value
(Pearson/
Fisher’s exact)		 p-value
(L-R test)
Genotype MM MN NN
Safety test Disc. Due to ADRs 26 11 9 0.54 0.08
Treatment completion 41 13 8
Efficacy
test 		Disc. Due to inadequate
efficacy		 33 11 5 0.9 0.02
Treatment completion 41 13 8
(d) Risperidone
CYP2D6 p-value
(Pearson/
Fisher’s
exact)		 p-value
(L-R
test)		 CYP3A5 p-value
(Pearson/
Fisher’s
exact)		 p-value
(L-R
test)
Genotype PM IM EM MM MN NN
Safety
test 		Disc. Due to ADRs 2 7 27 0.08 0.44 24 6 7 0.11 0.65
Treatment
completion		 5 7 87 63 28 8
Efficacy
test 		Disc. Due to
inadequate efficacy		 1 3 42 0.91 0.64 24 17 5 0.42 0.04
Treatment
completion		 5 7 87 63 28 8
(e) Ziprasidone
CYP3A5 p-value
(Pearson/
Fisher’s exact)		 p-value
(L-R test)
Genotype MM MN NN
Safety test Disc. Due to ADRs 19 8 5 0.6 0.77
Treatment completion 33 9 5
Efficacy
test 		Disc. Due to inadequate
efficacy		 13 7 3 0.5 0.08
Treatment completion 33 9 5

Abbreviations: Disc, Discontinuation; M, Mutant/lower activity allele; N, normal/higher activity allele; L, lower inducibility variant; H, higher inducibility allele; L-R, logistic regression.

*

Race-by-gene interaction term for FMO3 in the Olanzapine cohort was statistically significant in the safety test (p=0.05). Each race group was therefore analyzed separately, with the African-American group (N=59) reaching p=0.013.